Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Senl T7

Next Previous
Drug Profile

Senl T7

Alternative Names: CD7 CAR-T - Hebei Senlang Biotechnology; CD7 CART; Naturally selected anti-CD7 CAR T cells - Hebei Senlang Biotechnology; NS7CAR-T; S 101; SENL 101; Senl-T7; SenL-T7 CAR T Cells

Latest Information Update: 11 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebei Senlang Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I T-cell lymphoma
  • No development reported Leukaemia; Lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 18 Aug 2025 Phase-I clinical trial in T-cell lymphoma (Second-line therapy or greater) in China (Parenteral) (NCT07143929)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Lymphoma(Second-line therapy or greater) in China (Parenteral, Infusion)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Precursor-T-cell-lymphoblastic-leukaemia-lymphoma(Second-line therapy or greater) in China (Parenteral, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top